RenovoRx, Inc.

RenovoRx, Inc. (ticker: RNXT) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of RNXT's SEC filings surfaces 4 active risk signals, including 2 late-filing signals, and 2 auditor-change signals. RNXT reported $563K in revenue and -$3.52M for the period ending 2026-03-31, with operating cash flow of -$3.71M. Cash and equivalents stood at $12.36M (down 15.2% year-over-year). Total assets of $13.96M exceed total liabilities of $2.70M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

RNXT Cash Runway

Months-of-runway analysis for RNXT, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on RNXT

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.